ClinicalTrials.gg
CompletedNCT00033241Updated Jan 10, 2018

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

A Phase 1 interventional study of erlotinib hydrochloride and gemcitabine hydrochloride in Pancreatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by OSI Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-10.

Sponsored by OSI Pharmaceuticals (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2001, registered Apr 2002).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies testing erlotinib in Pancreatic Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. erlotinib · Pancreatic Neoplasms.

Started
2001
with 3 others
Phase 1
17 of 53
none open now
Registered
3rd of 53
by date
Lead sponsor
2 of 53
OSI Pharmaceuticals

Among the 53 studies testing erlotinib in Pancreatic Neoplasms, this one is one of 4 that started in 2001, is one of 17 in phase 1, and was the 3rd registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 53 studies testing erlotinib in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About erlotinib

erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing erlotinib in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with gemcitabine may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining erlotinib with gemcitabine in treating patients who have newly diagnosed locally advanced or metastatic pancreatic cancer or other solid tumors.

Read the detailed description

OBJECTIVES:

  • Determine the maximum tolerated dose of erlotinib in combination with gemcitabine in patients with recently diagnosed, gemcitabine-naive, locally advanced or metastatic pancreatic carcinoma or other potentially responsive solid tumor.
  • Determine the safety and tolerability of this regimen in these patients.
  • Determine the pharmacokinetics of this regimen in these patients.
  • Determine the objective antitumor response rate and response duration in patients treated with this regimen.
  • Determine the time to disease progression and duration of overall survival in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of erlotinib.

Patients receive gemcitabine IV over 30 minutes on day 1 of weeks 1-7 and oral erlotinib once daily beginning on day 3 of week 1 and continuing for 8 weeks (course 1). Patients receive subsequent courses of therapy comprising gemcitabine once weekly for 3 weeks and erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 12 additional patients are accrued and treated at the MTD as above.

Patients are followed at 30 days.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 3 months.

03

Conditions studied

  • Pancreatic Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Keywords

  • stage II pancreatic cancer
  • stage III pancreatic cancer
  • recurrent pancreatic cancer
  • unspecified adult solid tumor, protocol specific
  • stage IV pancreatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • or cytologically confirmed locally advanced or epithelial carcinoma of the pancreas or other considered to be potentially responsive to gemcitabine

    • Newly diagnosed or gemcitabine naive
  • Measurable or evaluable disease
  • Not amenable to surgical intervention due to medical or non-resectability of the tumor
  • No islet cell tumors or other non-epithelial cell carcinomas of the pancreas
  • No active or

    • Treated or asymptomatic brain metastases are allowed if on a stable dose of and/or there is no change in brain disease status for at least 4 weeks after related therapy (e.g., whole-brain radiotherapy)

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • 70-100%

:

  • Not specified

Hematopoietic:

  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic:

  • no greater than 2.0 mg/dL (except for documented Gilbert's syndrome)
  • or ALT less than 2 times (ULN) (no greater than 5 times ULN if hepatic obstruction or metastases present)
  • Albumin at least 2.5 g/dL

Renal:

  • Creatinine less than 1.5 times ULN OR
  • at least 60 mL/min

Cardiovascular:

  • No significant cardiovascular disease
  • No history of congestive heart failure currently requiring therapy
  • No ventricular arrhythmia requiring anti-arrhythmic therapy
  • No severe conduction disturbances
  • No angina pectoris requiring therapy
  • No myocardial infarction within the past 6 months

Gastrointestinal:

  • No significant gastrointestinal abnormalities including:

    • Requirement for IV alimentation
    • Active peptic ulcer disease

Ophthalmic:

  • No significant ophthalmologic abnormalities including:

    • Severe dry eye syndrome
    • Keratoconjunctivitis sicca
    • Sjogren's syndrome
    • Severe exposure keratopathy
    • Disorders that would increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)
    • Abnormal Schirmer test (less than 2 mm) allowed provided there is no evidence of corneal surface abnormalities

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No known or suspected to gemcitabine
  • No uncontrolled infection
  • negative
  • No other malignancy within the past 5 years except treated non-melanoma skin cancer or carcinoma in situ of the breast or cervix
  • No other life-threatening illness
  • No psychiatric disorders or altered mental status the would preclude or study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 28 days since prior immunotherapy or biological response modified therapy for the primary malignancy
  • No concurrent immunotherapy or biologic response modifier therapy for the primary malignancy

Chemotherapy:

  • See Disease Characteristics
  • At least 28 days since prior chemotherapy for the primary malignancy
  • No prior mitomycin or nitrosoureas for the primary malignancy
  • No more than 6 prior courses of chemotherapy with an alkylating agent for the primary malignancy
  • No prior gemcitabine for the primary malignancy except as a low-dose (less than 500 mg/m\^2) radiosensitizer administered concurrently with or within 2 weeks after radiotherapy at least 3 months ago
  • No other concurrent chemotherapy for the primary malignancy

Endocrine therapy:

  • See Disease Characteristics
  • At least 28 days since prior systemic hormonal therapy (except LH-RH agonists) for the primary malignancy
  • No concurrent systemic hormonal therapy (except LH-RH agonists) for the primary malignancy
  • Other concurrent endocrine therapy is allowed as follows:

    • Hormonal therapy (e.g., megestrol) for appetite stimulation
    • Nasal, ophthalmic, or topical glucocorticoids
    • Oral glucocorticoids for adrenal insufficiency
    • Low-dose maintenance steroids

Radiotherapy:

  • See Disease Characteristics
  • At least 28 days since prior radiotherapy for the primary malignancy or metastases and recovered
  • No prior wide-field radiotherapy to 25% or more of marrow-bearing bone
  • No prior pelvic irradiation
  • No concurrent radiotherapy for the primary malignancy or metastases
  • No concurrent wide-field radiotherapy for pain management

Surgery:

  • See Disease Characteristics
  • Recovered from any prior surgery
  • No prior surgical procedures affecting absorption

Other:

  • No prior agent for the primary malignancy targeting the epidermal growth factor receptor (EGFR) or EGFR-specific tyrosine kinase activity
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
06

Study locations

2 sites
  • Arizona Cancer Center at University of Arizona Health Sciences Center
    Tucson, Arizona 85724, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 78229-3271, United States
07

References and documents

Publications

  • Dragovich T, Patnaik A, Rowinsky EK, et al.: A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-895, 2003.
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2001 to primary completion in Apr 2004, 32 months.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's 32 months is below that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2002
First posted
Jan 27, 2003
StartActual
Jul 23, 2001
Primary completionActual
Apr 22, 2004
CompletionActual
Apr 22, 2004
Last update
Jan 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00033241
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
Jul 23, 2001
Primary completion
Apr 22, 2004
Completion
Apr 22, 2004
Last update
Jan 10, 2018

Study contacts

Pedro Santabarbara, MD
study chair · OSI Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erlotinib · Gemcitabine

Start the discussion